02/14/2025
Positive news in the fight against glioblastoma! MimiVax's Phase 2b clinical trial, SURVIVE, evaluating SurVaxM in newly diagnosed patients, has successfully completed its first interim analysis. The data provides encouraging insights supporting the continuation of the trial and its goal of improving outcomes beyond standard treatment. This is a significant step forward in exploring a potential new treatment approach for this aggressive cancer.
100% of our proceeds go directly to the SurVaxM vaccine. Exciting to see what MimiVax and Roswell have done and looking forward to the continued success
Read the full press release for details on this important milestone. https://social.prnewswire.com/s/dLDfXDYLBkAXSKTrqlZpmQ